{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:26:51Z","timestamp":1763036811773,"version":"build-2065373602"},"reference-count":100,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Postgraduate School of Molecular Medicine"},{"name":"EU","award":["FP7-REGPOT-2012-CT2012-316254-BASTION"],"award-info":[{"award-number":["FP7-REGPOT-2012-CT2012-316254-BASTION"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.bcmd.2014.01.001","type":"journal-article","created":{"date-parts":[[2014,2,3]],"date-time":"2014-02-03T02:16:32Z","timestamp":1391393792000},"page":"77-83","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["BRAF \u2014 A new player in hematological neoplasms"],"prefix":"10.1016","volume":"53","author":[{"given":"Marcin M.","family":"Machnicki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomasz","family":"Stoklosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2014.01.001_bb0005","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.bcmd.2014.01.001_bb0010","first-page":"3733","article-title":"95-kilodalton B-Raf serine\/threonine kinase: identification of the protein and its major autophosphorylation site","volume":"12","author":"Stephens","year":"1992","journal-title":"Mol. Cell. Biol."},{"article-title":"BRAF (v-raf murine sarcoma viral oncogene homolog B1)","year":"2004","author":"Domingo","key":"10.1016\/j.bcmd.2014.01.001_bb0015"},{"key":"10.1016\/j.bcmd.2014.01.001_bb0020","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nature05610","article-title":"Patterns of somatic mutation in human cancer genomes","volume":"446","author":"Greenman","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.bcmd.2014.01.001_bb0025","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ccr.2004.09.022","article-title":"Guilty as charged: B-RAF is a human oncogene","volume":"6","author":"Garnett","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bcmd.2014.01.001_bb0030","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S0092-8674(04)00215-6","article-title":"Mechanism of activation of the RAF\u2013ERK signaling pathway by oncogenic mutations of B-RAF","volume":"116","author":"Wan","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.bcmd.2014.01.001_bb0035","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/sj.onc.1202367","article-title":"Constitutive activation of the 41-\/43-kDa mitogen-activated protein kinase signaling pathway in human tumors","volume":"18","author":"Hoshino","year":"1999","journal-title":"Oncogene"},{"key":"10.1016\/j.bcmd.2014.01.001_bb0040","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/ng1054","article-title":"High frequency of BRAF mutations in nevi","volume":"33","author":"Pollock","year":"2003","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bcmd.2014.01.001_bb0045","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/nature03890","article-title":"BRAFE600-associated senescence-like cell cycle arrest of human naevi","volume":"436","author":"Michaloglou","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.bcmd.2014.01.001_bb0050","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.1158\/1078-0432.CCR-10-3349","article-title":"BRAF activation induces transformation and then senescence in human neural stem cells: a pilocytic astrocytoma model","volume":"17","author":"Raabe","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcmd.2014.01.001_bb0055","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0092-8674(00)81902-9","article-title":"Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a","volume":"88","author":"Serrano","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.bcmd.2014.01.001_bb0060","first-page":"5198","article-title":"Suppression of BRAF(V599E) in human melanoma abrogates transformation","volume":"63","author":"Hingorani","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcmd.2014.01.001_bb0065","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nature04304","article-title":"BRAF mutation predicts sensitivity to MEK inhibition","volume":"439","author":"Solit","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.bcmd.2014.01.001_bb0070","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1038\/sj.bjc.6604783","article-title":"KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer","volume":"99","author":"Nakayama","year":"2008","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bcmd.2014.01.001_bb0075","doi-asserted-by":"crossref","first-page":"e47054","DOI":"10.1371\/journal.pone.0047054","article-title":"The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis","volume":"7","author":"Safaee Ardekani","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bcmd.2014.01.001_bb0080","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1002\/cncr.26500","article-title":"The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis","volume":"118","author":"Kim","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.bcmd.2014.01.001_bb0085","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/cncr.27782","article-title":"BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer","volume":"119","author":"Grisham","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.bcmd.2014.01.001_bb0090","doi-asserted-by":"crossref","first-page":"5705","DOI":"10.1200\/JCO.2008.18.0786","article-title":"Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer","volume":"26","author":"Di Nicolantonio","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcmd.2014.01.001_bb0095","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2014.01.001_bb0100","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1677\/ERC-08-0101","article-title":"Mutational analysis of the BRAF, RAS and EGFR genes in human adrenocortical carcinomas","volume":"16","author":"Kotoula","year":"2009","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.bcmd.2014.01.001_bb0105","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/PDM.0b013e31826c7fe0","article-title":"BRAF V600E mutations in endometrial adenocarcinoma","volume":"22","author":"He","year":"2013","journal-title":"Diagn. Mol. Pathol."},{"key":"10.1016\/j.bcmd.2014.01.001_bb0110","doi-asserted-by":"crossref","first-page":"4757","DOI":"10.1038\/sj.onc.1206705","article-title":"Mutations of the BRAF gene in squamous cell carcinoma of the head and neck","volume":"22","author":"Weber","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.bcmd.2014.01.001_bb0115","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/jnci\/95.8.625","article-title":"BRAF mutation in papillary thyroid carcinoma","volume":"95","author":"Cohen","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.bcmd.2014.01.001_bb0120","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1200\/JCO.2011.35.9638","article-title":"Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations","volume":"29","author":"Marchetti","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcmd.2014.01.001_bb0125","doi-asserted-by":"crossref","first-page":"e259","DOI":"10.1038\/cddis.2011.136","article-title":"BRAF and PIK3CA genes are somatically mutated in hepatocellular carcinoma among patients from South Italy","volume":"3","author":"Colombino","year":"2012","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bcmd.2014.01.001_bb0130","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/gut.52.5.706","article-title":"Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma","volume":"52","author":"Tannapfel","year":"2003","journal-title":"Gut"},{"key":"10.1016\/j.bcmd.2014.01.001_bb0135","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1056\/NEJMoa1014209","article-title":"BRAF mutations in hairy-cell leukemia","volume":"364","author":"Tiacci","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2014.01.001_bb0140","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2011-08-368209","article-title":"The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms","volume":"119","author":"Arcaini","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2014.01.001_bb0145","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1038\/onc.2009.73","article-title":"Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma","volume":"28","author":"Jones","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.bcmd.2014.01.001_bb0150","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00401-011-0802-6","article-title":"Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma","volume":"121","author":"Schindler","year":"2011","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.bcmd.2014.01.001_bb0155","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/blood-2010-04-279083","article-title":"Recurrent BRAF mutations in Langerhans cell histiocytosis","volume":"116","author":"Badalian-Very","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2014.01.001_bb0160","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1200\/JCO.2012.46.9676","article-title":"BRAF mutations in Erdheim\u2013Chester disease","volume":"31","author":"Emile","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcmd.2014.01.001_bb0165","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1182\/blood-2012-05-430140","article-title":"High prevalence of BRAF V600E mutations in Erdheim\u2013Chester disease but not in other non-Langerhans cell histiocytoses","volume":"120","author":"Haroche","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2014.01.001_bb0170","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1126\/science.1124642","article-title":"Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome","volume":"311","author":"Rodriguez-Viciana","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.bcmd.2014.01.001_bb0175","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.ejca.2012.11.004","article-title":"BRAF inhibitor activity in V600R metastatic melanoma","volume":"49","author":"Klein","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bcmd.2014.01.001_bb0180","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1479-5876-8-67","article-title":"Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032","volume":"8","author":"Rubinstein","year":"2010","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.bcmd.2014.01.001_bb0185","doi-asserted-by":"crossref","first-page":"418672","DOI":"10.1155\/2012\/418672","article-title":"Novel BRAF alteration in a sporadic pilocytic astrocytoma","volume":"2012","author":"Dahiya","year":"2012","journal-title":"Case Rep. Med."},{"key":"10.1016\/j.bcmd.2014.01.001_bb0190","doi-asserted-by":"crossref","first-page":"D945","DOI":"10.1093\/nar\/gkq929","article-title":"COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer","volume":"39","author":"Forbes","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bcmd.2014.01.001_bb0195","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/nature09454","article-title":"Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma","volume":"467","author":"Bollag","year":"2010","journal-title":"Nature"},{"issue":"12 Suppl","key":"10.1016\/j.bcmd.2014.01.001_bb0200","doi-asserted-by":"crossref","first-page":"B88","DOI":"10.1158\/1535-7163.TARG-09-B88","article-title":"Abstract B88: a selective Raf kinase inhibitor induces cell death and tumor regression of human cancer cell lines encoding B-Raf V600E mutation","volume":"8","author":"Laquerre","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bcmd.2014.01.001_bb0205","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.bcmd.2014.01.001_bb0210","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nature10868","article-title":"Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR","volume":"483","author":"Prahallad","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.bcmd.2014.01.001_bb0215","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nature10662","article-title":"RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)","volume":"480","author":"Poulikakos","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.bcmd.2014.01.001_bb0220","doi-asserted-by":"crossref","first-page":"20411","DOI":"10.1073\/pnas.0905833106","article-title":"MEK1 mutations confer resistance to MEK and B-RAF inhibition","volume":"106","author":"Emery","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcmd.2014.01.001_bb0225","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2014.01.001_bb0230","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S1470-2045(12)70431-X","article-title":"Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial","volume":"13","author":"Long","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bcmd.2014.01.001_bb0235","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1136\/jclinpath-2012-201345","article-title":"The somatic affairs of BRAF: tailored therapies for advanced malignant melanoma and orphan non-V600E (V600R-M) mutations","volume":"66","author":"Ponti","year":"2013","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.bcmd.2014.01.001_bb0240","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2010.28.15_suppl.3534","article-title":"PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors","volume":"28","author":"Kopetz","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcmd.2014.01.001_bb0245","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1089\/thy.2013.0057","article-title":"Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring V600EBRAF mutation","volume":"23","author":"Kim","year":"2013","journal-title":"Thyroid"},{"key":"10.1016\/j.bcmd.2014.01.001_bb0250","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.leukres.2011.12.015","article-title":"Incidence of the BRAF V600E mutation in chronic lymphocytic leukaemia and prolymphocytic leukaemia","volume":"36","author":"Langabeer","year":"2012","journal-title":"Leuk. Res."},{"key":"10.1016\/j.bcmd.2014.01.001_bb0255","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.3109\/10428194.2012.742525","article-title":"BRAF mutations in chronic lymphocytic leukemia","volume":"54","author":"Jebaraj","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.bcmd.2014.01.001_bb0260","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1038\/leu.2011.163","article-title":"Sequence analysis of 515 kinase genes in chronic lymphocytic leukemia","volume":"25","author":"Zhang","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.bcmd.2014.01.001_bb0265","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/ng.1032","article-title":"Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia","volume":"44","author":"Quesada","year":"2012","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bcmd.2014.01.001_bb0270","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/sj.leu.2403201","article-title":"BRAF mutations in acute leukemias","volume":"18","author":"Lee","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.bcmd.2014.01.001_bb0275","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/sj.leu.2403589","article-title":"Mutations in the BRAF and N-ras genes in childhood acute lymphoblastic leukaemia","volume":"19","author":"Gustafsson","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.bcmd.2014.01.001_bb0280","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/sj.leu.2402787","article-title":"Mutation of BRAF is uncommon in AML FAB type M1 and M2","volume":"17","author":"Smith","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.bcmd.2014.01.001_bb0285","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1038\/leu.2008.14","article-title":"BRAF mutations are very rare in B- and T-cell pediatric acute lymphoblastic leukemias","volume":"22","author":"Davidsson","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.bcmd.2014.01.001_bb0290","doi-asserted-by":"crossref","first-page":"6803","DOI":"10.1158\/0008-5472.CAN-08-0101","article-title":"Mutation of genes affecting the RAS pathway is common in childhood acute lymphoblastic leukemia","volume":"68","author":"Case","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcmd.2014.01.001_bb0295","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.3109\/10428194.2012.668188","article-title":"Absence of BRAF V600E mutation in a cohort of 402 patients with various chronic and acute myeloid neoplasms","volume":"53","author":"Trifa","year":"2012","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.bcmd.2014.01.001_bb0300","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1038\/sj.bjc.6601371","article-title":"BRAF mutations in non-Hodgkin's lymphoma","volume":"89","author":"Lee","year":"2003","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bcmd.2014.01.001_bb0305","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1073\/pnas.1121343109","article-title":"Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing","volume":"109","author":"Lohr","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcmd.2014.01.001_bb0310","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1038\/modpathol.2012.73","article-title":"Thyroid carcinoma-associated genetic mutations also occur in thyroid lymphomas","volume":"25","author":"Aggarwal","year":"2012","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.bcmd.2014.01.001_bb0315","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1038\/sj.leu.2403116","article-title":"BRAF gene is not mutated in plasma cell leukemia and multiple myeloma","volume":"17","author":"Bonello","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.bcmd.2014.01.001_bb0320","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1046\/j.1365-2141.2003.04664.x","article-title":"Alterations of RAS signalling in Chinese multiple myeloma patients: absent BRAF and rare RAS mutations, but frequent inactivation of RASSF1A by transcriptional silencing or expression of a non-functional variant transcript","volume":"123","author":"Ng","year":"2003","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcmd.2014.01.001_bb0325","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/sj.leu.2403286","article-title":"BRAF gene is not mutated in mismatch repair-proficient or -deficient plasma cell dyscrasias","volume":"18","author":"Velangi","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.bcmd.2014.01.001_bb0330","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nature09837","article-title":"Initial genome sequencing and analysis of multiple myeloma","volume":"471","author":"Chapman","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.bcmd.2014.01.001_bb0335","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/ajh.23339","article-title":"Genome-wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles","volume":"88","author":"Mosca","year":"2013","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2014.01.001_bb0340","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/j.1365-2141.2011.08868.x","article-title":"High resolution melting analysis for detection of BRAF exon 15 mutations in hairy cell leukaemia and other lymphoid malignancies","volume":"155","author":"Boyd","year":"2011","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcmd.2014.01.001_bb0345","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1158\/2159-8290.CD-13-0014","article-title":"Targeting the BRAF V600E mutation in multiple myeloma","volume":"3","author":"Andrulis","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bcmd.2014.01.001_bb0350","doi-asserted-by":"crossref","first-page":"6455","DOI":"10.1038\/sj.onc.1206739","article-title":"BRAF mutations in papillary carcinomas of the thyroid","volume":"22","author":"Fukushima","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.bcmd.2014.01.001_bb0355","doi-asserted-by":"crossref","first-page":"780","DOI":"10.3324\/haematol.2011.054874","article-title":"Detection of BRAF mutations in patients with hairy cell leukemia and related lymphoproliferative disorders","volume":"97","author":"Blombery","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.bcmd.2014.01.001_bb0360","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3324\/haematol.2012.078071","article-title":"Constant activation of the RAF\u2013MEK\u2013ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia","volume":"98","author":"Tiacci","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.bcmd.2014.01.001_bb0365","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1365-2141.2011.08931.x","article-title":"Revised guidelines for the diagnosis and management of hairy cell leukaemia and hairy cell leukaemia variant*","volume":"156","author":"Jones","year":"2012","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcmd.2014.01.001_bb0370","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/blood-2009-06-195370","article-title":"How I treat hairy cell leukemia","volume":"115","author":"Grever","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2014.01.001_bb0375","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/hon.975","article-title":"Hairy cell leukaemia: biological and clinical overview from immunogenetic insights","volume":"29","author":"Forconi","year":"2011","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.bcmd.2014.01.001_bb0380","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1182\/blood-2011-09-379339","article-title":"Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation","volume":"119","author":"Xi","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2014.01.001_bb0385","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1097\/PAS.0b013e3182549b50","article-title":"Application of a BRAF V600E mutation-specific antibody for the diagnosis of hairy cell leukemia","volume":"36","author":"Andrulis","year":"2012","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.bcmd.2014.01.001_bb0390","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1182\/blood-2011-10-383323","article-title":"Development and validation of a real-time quantification assay to detect and monitor BRAFV600E mutations in hairy cell leukemia","volume":"119","author":"Schnittger","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2014.01.001_bb0395","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1365-2141.2009.07668.x","article-title":"Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis","volume":"145","author":"Else","year":"2009","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcmd.2014.01.001_bb0400","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1056\/NEJMc1202124","article-title":"BRAF inhibition in refractory hairy-cell leukemia","volume":"366","author":"Dietrich","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2014.01.001_bb0405","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/bjh.12201","article-title":"Rapid response of biallelic BRAF V600E mutated hairy cell leukaemia to low dose vemurafenib","volume":"161","author":"Follows","year":"2013","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcmd.2014.01.001_bb0410","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.3324\/haematol.2012.082404","article-title":"Low-dose vemurafenib induces complete remission in a case of hairy-cell leukemia with a V600E mutation","volume":"98","author":"Peyrade","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.bcmd.2014.01.001_bb0415","doi-asserted-by":"crossref","first-page":"5332","DOI":"10.1182\/blood-2011-12-400374","article-title":"Absence of BRAF-V600E in the human cell lines BONNA-12, ESKOL, HAIR-M, and HC-1 questions their origin from hairy cell leukemia","volume":"119","author":"Tiacci","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2014.01.001_bb0420","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/leu.2012.163","article-title":"Hairy cell leukemia cell lines expressing annexin A1 and displaying B-cell receptor signals characteristic of primary tumor cells lack the signature BRAF mutation to reveal unrepresentative origins","volume":"27","author":"Weston-Bell","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.bcmd.2014.01.001_bb0425","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.ctrv.2010.02.012","article-title":"Langerhans cell histiocytosis: current concepts and treatments","volume":"36","author":"Abla","year":"2010","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bcmd.2014.01.001_bb0430","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1365-2141.2011.08915.x","article-title":"Recent advances in the understanding of Langerhans cell histiocytosis","volume":"156","author":"Badalian-Very","year":"2012","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcmd.2014.01.001_bb0435","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/qjmed\/hcq206","article-title":"Langerhans cell histiocytosis: old disease new treatment","volume":"104","author":"Ng-Cheng-Hin","year":"2011","journal-title":"QJM"},{"key":"10.1016\/j.bcmd.2014.01.001_bb0440","first-page":"388","article-title":"Erdheim\u2013Chester disease: an orphan condition seeking treatment","volume":"14","author":"Mazor","year":"2012","journal-title":"Isr. Med. Assoc. J."},{"key":"10.1016\/j.bcmd.2014.01.001_bb0445","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/00005792-199605000-00005","article-title":"Erdheim\u2013Chester disease. Clinical and radiologic characteristics of 59 cases","volume":"75","author":"Veyssier-Belot","year":"1996","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.bcmd.2014.01.001_bb0450","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1182\/blood-2010-06-294108","article-title":"CNS involvement and treatment with interferon-alpha are independent prognostic factors in Erdheim\u2013Chester disease: a multicenter survival analysis of 53 patients","volume":"117","author":"Arnaud","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2014.01.001_bb0455","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev-pathol-020712-163959","article-title":"Pathogenesis of Langerhans cell histiocytosis","volume":"8","author":"Badalian-Very","year":"2013","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.bcmd.2014.01.001_bb0460","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S0046-8177(99)90228-9","article-title":"Chester\u2013Erdheim disease: a neoplastic disorder","volume":"30","author":"Chetritt","year":"1999","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.bcmd.2014.01.001_bb0465","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJM199407213310303","article-title":"Langerhans'-cell histiocytosis (histiocytosis X)\u2014a clonal proliferative disease","volume":"331","author":"Willman","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2014.01.001_bb0470","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1182\/blood-2012-06-429597","article-title":"BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis","volume":"120","author":"Sahm","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2014.01.001_bb0475","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/gcc.22010","article-title":"Identification of the V600D mutation in Exon 15 of the BRAF oncogene in congenital, benign Langerhans cell histiocytosis","volume":"52","author":"Kansal","year":"2013","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.bcmd.2014.01.001_bb0480","doi-asserted-by":"crossref","first-page":"e33891","DOI":"10.1371\/journal.pone.0033891","article-title":"B-RAF mutant alleles associated with Langerhans cell histiocytosis, a granulomatous pediatric disease","volume":"7","author":"Satoh","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bcmd.2014.01.001_bb0485","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/WNO.0b013e31820a204e","article-title":"Presence of Erdheim\u2013Chester disease and Langerhans cell histiocytosis in the same patient: a report of 2 cases","volume":"31","author":"Pineles","year":"2011","journal-title":"J. Neuroophthalmol."},{"key":"10.1016\/j.bcmd.2014.01.001_bb0490","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1182\/blood-2012-07-446286","article-title":"Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim\u2013Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation","volume":"121","author":"Haroche","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2014.01.001_bb0495","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nature08833","article-title":"RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth","volume":"464","author":"Hatzivassiliou","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.bcmd.2014.01.001_bb0500","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1378\/chest.12-1917","article-title":"Pulmonary Langerhans cell histiocytosis: profiling of multifocal tumors using next-generation sequencing identifies concordant occurrence of BRAF V600E mutations","volume":"143","author":"Yousem","year":"2013","journal-title":"Chest"}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979614000023?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979614000023?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:30:15Z","timestamp":1761049815000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979614000023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":100,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S1079979614000023"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2014.01.001","relation":{},"ISSN":["1079-9796"],"issn-type":[{"type":"print","value":"1079-9796"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BRAF \u2014 A new player in hematological neoplasms","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2014.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}